Nanobiotix S.A.
NBTX
Rank in Stocks
#6679
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Share Price
$32.03
Last synced: 2026-11-09
Market Cap
$1.63B
Change (1 day)
4.57%
Change (1 year)
48.42%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Nanobiotix S.A. (NBTX)
Category
Healthcare
EPS for Nanobiotix S.A. (NBTX)
EPS as of June 2026 TTM: $-1.23
According to Nanobiotix S.A.'s latest financial reports, its current EPS (TTM) is $-1.23. At the end of 2025 the company had an EPS of $-0.59, an increase over its 2024 EPS of $-1.50.
EPS history for Nanobiotix S.A. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.23 | 107.92% |
| 2025 | $-0.59 | -60.85% |
| 2024 | $-1.50 | 25.50% |
| 2023 | $-1.19 | -32.13% |
| 2022 | $-1.76 | 14.60% |
| 2021 | $-1.54 | -8.66% |
| 2020 | $-1.68 | -36.26% |
| 2019 | $-2.64 | 50.95% |
| 2018 | $-1.75 | -2.96% |
| 2017 | $-1.80 | 19.63% |
| 2016 | $-1.50 | 15.47% |
| 2015 | $-1.30 | 45.52% |
| 2014 | $-0.90 | -14.32% |
| 2013 | $-1.05 | 21.89% |
| 2012 | $-0.86 | -80.63% |
| 2011 | $-4.43 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,376.60% |
US
|
|
| $-7.07 | 476.34% |
US
|
|
| $-5.29 | 331.24% |
AU
|
|
| $12.88 | -1,149.98% |
BE
|
|
| $21.56 | -1,857.56% |
NL
|
Questions about Nanobiotix S.A.'s earnings per share (EPS)
What is Nanobiotix S.A.'s earnings per share (EPS)?
Nanobiotix S.A.'s earnings per share (EPS) over the last twelve months is $-1.23, as of Jun 2026.
What was Nanobiotix S.A.'s earnings per share (EPS) in 2025?
In 2025, Nanobiotix S.A.'s earnings per share (EPS) was $-0.59, compared with $-1.50 in 2024.
How has Nanobiotix S.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Nanobiotix S.A.'s earnings per share (EPS) was highest in 2025 ($-0.59) and lowest in 2022 ($-1.76).
How does Nanobiotix S.A.'s earnings per share (EPS) compare with similar companies?
Nanobiotix S.A.'s earnings per share (EPS) ($-1.23) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.